Elanco Animal Health (NYSE:ELAN) Rating Increased to Overweight at JPMorgan Chase & Co.

Elanco Animal Health (NYSE:ELAN) was upgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report released on Tuesday,Benzinga reports. The brokerage presently has a $24.00 price objective on the stock, up from their prior price objective of $18.00. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 16.05% from the stock’s previous close.

A number of other equities research analysts have also recently commented on ELAN. Piper Sandler raised their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Wall Street Zen upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. UBS Group upped their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Stifel Nicolaus upped their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Finally, Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $19.14.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $20.68 on Tuesday. Elanco Animal Health has a one year low of $8.02 and a one year high of $20.92. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The firm has a market cap of $10.27 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 3.83 and a beta of 1.65. The firm’s fifty day moving average is $17.86 and its two-hundred day moving average is $14.19.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors have recently bought and sold shares of the company. MTM Investment Management LLC grew its position in Elanco Animal Health by 5.5% in the 2nd quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock valued at $218,000 after acquiring an additional 800 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Elanco Animal Health by 7.0% in the first quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock valued at $131,000 after purchasing an additional 810 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Elanco Animal Health by 8.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock worth $169,000 after buying an additional 944 shares in the last quarter. M&T Bank Corp lifted its holdings in Elanco Animal Health by 4.0% during the 2nd quarter. M&T Bank Corp now owns 25,029 shares of the company’s stock worth $358,000 after buying an additional 971 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Elanco Animal Health by 8.7% during the 2nd quarter. ProShare Advisors LLC now owns 12,439 shares of the company’s stock worth $178,000 after buying an additional 999 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.